Insights & Analysis

Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

All News Activism M&A Podcasts Private Cos. Private Equity Restructuring Scoops & Exclusives SPACs
Activism

Activist Investing Today: Litt Targets REIT CEO Pay

By Ronald Orol
|
Published: July 3rd, 2025
Real estate activist Jonathan Litt discusses concerns that REIT boards often identify distorted peer groups to justify problematic executive pay, as well as why specific directors at 15 REITs should face vote-no campaigns.
Activism

Activist Investing Today: Skadden's Breheny on Expected SEC Shifts

By Ronald Orol
|
Published: June 13th, 2025
Brian Breheny, the former chief of the SEC's M&A division, discusses expected changes to regulations affecting activist investors, including why he thinks the nation's securities regulator can eliminate activist shareholder proposals.
Activism

Activist Investing Today: Eldar on Anti-Activist Pill Evolution

By Ronald Orol
|
Published: May 23rd, 2025
When corporations install anti-activist poison pills they're less likely to implement new share buybacks and their operationally focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.
Activism

Pills Emerge Amid Tariff Uncertainty, Activism

By Ronald Orol
|
Published: April 28th, 2025
As the markets face tariff-related volatility, some companies, especially biotechnology and pharmaceuticals companies, are setting up or extending shareholder rights plans, known as poison pills, to discourage unsolicited bidders and activist accumulations.
 Company
Solutions
Contact The Deal
Tel:
+1 646 891 2135
International:
+44 (0) 20 7832 6500
Email:
[email protected]
© 2025 The Deal.

A With Intelligence company. All rights reserved. Privacy Policy, Cookies, Terms, Modern Slavery Act